support:13376277882 | tech@naturebios.com

HLA-F Mouse mAb[U82G]Cat NO.: A86621

Western blot(SDS PAGE) analysis of extracts from Raji cells.Using HLA-F Mouse mAb IgG [U82G] at dilution of 1:1000 incubated at 4℃ over night.

  • SizePriceIn stock
  • 100ul2088.00库存充足
  • 200ul3098.00库存充足
Order Datasheet

Product information

Protein names :HLA-F,HLA-5.4,HLAF,HLAF_HUMAN,HLA class I histocompatibility antigen, alpha chain F

UniProtID :P30511

MASS(da) :39,062

MW(kDa) :40kda

Form :Liquid

Purification :Protein A purification

Host :Mouse

Isotype :IgG

sensitivity :Endogenous

Reactivity :Human

  • ApplicationDilution
  • 免疫印迹(WB)1:1000-2000
  • 免疫组化(IHC)1:100
  • The optimal dilutions should be determined by the end user

Specificity :Antibody is produced by immunizing animals with a synthetic peptide of human HLA-F.

Storage :Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol. Shipped at 4°C. Store at-20°C or -80°C. Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

WB Positive detected :Raji cells

Function : Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors (PubMed:28636952). Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production (PubMed:27455421). Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions (PubMed:24018270). May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses (PubMed:23851683). May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464)..

Tissue specificity :Expressed in resting B cells (at protein level). Expressed in secondary lymphoid organs rich in B and T cells such as the tonsils, spleen, and thymus (at protein level) (PubMed:10605026, PubMed:11169396). Expressed in the endothelial cells of the tonsils (PubMed:11169396). Expressed on activated lymphoid cells including B cells, NK cells, CD4+ T cells and memory T cells (at protein level) (PubMed:27455421, PubMed:20865824). Expressed in motor neurons of spinal cord (PubMed:26928464)..

Subcellular locationi :Cell membrane,Single-pass type I membrane protein. Early endosome membrane. Lysosome membrane.

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v BSA, 1X TBST at 4°C overnight.